Ignite Creation Date:
2024-05-06 @ 3:30 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04655599
Status:
TERMINATED
Last Update Posted:
2021-05-17
First Post:
2020-11-19
Brief Title:
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
Sponsor:
Arena Pharmaceuticals
Organization:
Arena Pharmaceuticals
Study Overview
Official Title:
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
Status:
TERMINATED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Strategic business decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome IBS
Detailed Description:
This is a single-center randomized crossover double-blind placebo-controlled study designed to evaluate the effects of olorinab on gastric small-bowel and colonic transit in IBS participants with predominant constipation IBS-C or with predominant diarrhea IBS-D
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None